Tekmira Begins Dosing Patients in Phase I Trial of Cancer Drug

The phase I trial is an open-label, multi-dose, dose-escalation study designed to
evaluate the safety, tolerability, and pharmacokinetics of TKM-PLK1, as well as determine the therapy's maximum tolerated dose.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.